Neurocrine Biosciences has presented a new analysis of data from the KINECT 3 Phase III trial of Ingrezza (valbenazine) showing improved outcomes for tardive dyskinesia (TD) patients.
The data show treatment with the vesicular monoamine transporter 2 (VMAT2) inhibitor improved TD symptoms regardless of body region.
The US Food and Drug Administration approved Ingrezza, the first treatment for TD in the USA, in April last year.
Chief medical officer Eiry Roberts said: “We believe these data are important since patients’ experience with tardive dyskinesia can be highly variable in terms of the body region impacted by uncontrollable movements.”
“In addition, data analyses from our open-label long-term study show improvement in clinician and patient-reported outcomes.”